IDIVAL evaluates the activity of its research groups in its External Scientific Council

This advisory body meets regularly and ensures the scientific quality of the institute.

The members of the External Scientific Council of the Marqués de Valdecilla Health Research Institute (IDIVAL) met last week at IDIVAL and online in order to evaluate the activity of some research groups of the center, as well as to monitor the Strategic Plan 2022-2026.

For the evaluation, the principal investigators (PIs) of each group gave a fifteen-minute presentation followed by a 30-minute discussion with the members of the board.

The groups evaluated at this meeting were the Nanomedicine Group; the Hematological Neoplasms and Hematopoietic Progenitor Transplantation Group; the Medical Oncology Group and the Neurodegenerative Diseases Group.

Likewise, the advance of the 2023 report was presented, which reflects the most relevant information of the institute for the past year in terms of scientific production, patronage or the program for the promotion of research, among others.

The External Scientific Council ensures the scientific quality of the institute

The External Scientific Council is a consultative body in charge of advising on IDIVAL’s scientific activities, as well as ensuring its scientific quality as indicated in the Statutes and in IDIVAL’s Rules of Organization and Operation.

It is made up of experts in the field of health sciences of recognized prestige in the scientific community and is appointed by the Board of Trustees at the proposal of the scientific management of IDIVAL. It is chaired by Ángel Carracedo Álvarez, Professor of Legal Medicine at the University of Santiago de Compostela and has ten members:

• Xosé Ramón Bustelo. Director of the Genomics and Proteomics Unit of the Cancer Research Center. CSIC-University of Salamanca. Cancer Research Center
• Rafael Cantón Moreno. Head of the Microbiology Department, Hospital Ramón y Cajal. Complutense University of Madrid. IRYCIS
• Miguel Delgado Rodríguez. Professor of Preventive Medicine and Public Health, University of Jaén
• Jordi Vila Estapé. Head of the Microbiology Department of the Clinical Hospital of Barcelona. University of Barcelona. CRESI
• Ana María Zubiaga Elordieta. Professor of Genetics, University of the Basque Country, Faculty of Science and Technology. Head of the Genomics Service of the UPV/EHU
• María Luz Martínez-Chantar. Group Leader Researcher at CIC bioGUNE
• Francisco Sánchez Madrid. Scientific Director of IIS-Princesa, Head of Service and Professor of Immunology. Hospital Universitario de La Princesa, Universidad Autónoma de Madrid.
• Nuria Monserrat Pulido. Institute of Bioengineering of Catalonia and coordinator of the Biomodels and Biobanks Platform of the Carlos III Institute of Health
• María Buti Ferret. Clinical Chief of Internal Medicine, Hospital General/ Vall d’Hebron Research Institute (VHIR). Professor at the Autonomous University of Barcelona
• Ana Fernández-Sesma. Researcher at Mount Sinai Hospital School of Medicine, New York